Therapeutic implications of GIPC1 silencing in cancer

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Chittenden, Thomas W ^a,b,c   Pak, Jane ^a   Rubio, Renee ^a   Cheng, Hailing ^d   Holton, Kristina ^a   Prendergast, Niall ^a   Glinskii, Vladimir ^a   Cai, Yi ^a   Culhane, Aedin ^a,b   Bentink, Stefan ^a,b   Schwede, Mathew ^a   Mar, Jessica C ^a,b   Howe, Eleanor A ^a,c   Aryee, Martin ^e   Sultana, Razvan ^a   Lanahan, Anthony A ^f   Taylor, Jennifer M ^g   Holmes, Chris ^c,h   Hahn, William C ^a,i   Zhao, Jean J ^d   Iglehart, J Dirk ^d   Quackenbush, John ^a,b   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CSIRO   (Australia)

^h MRC MAMMALIAN GENETICS UNIT   (United Kingdom)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN GIPC1; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GIPC1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL CULTURE; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; EPITHELIUM CELL; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; BREAST TUMOR; CELL TRANSFORMATION; COLORECTAL TUMOR; CYTOLOGY; DISEASE COURSE; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 78651232266     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015581     Document Type: Article

References (36)

1. Katoh M (2002) GIPC gene family (Review). Int J Mol Med 9: 585-589.
2. Chittenden TW, Claes F, Lanahan AA, Autiero M, Palac RT, et al. (2006) Selective regulation of arterial branching morphogenesis by synectin. Dev Cell 10: 783-795.
3. Lanahan AA, Chittenden TW, Mulvihill E, Smith K, Schwartz S, et al. (2006) Synectin-dependent gene expression in endothelial cells. Physiol Genomics 27: 380-390.
4. Kato H, Ohno K, Hashimoto K, Sato K (2004) Synectin in the nervous system: expression pattern and potential as a binding partner of neurotrophin receptors. FEBS Lett 572: 123-128.
5. Lou X, Yano H, Lee F, Chao MV, Farquhar MG (2001) GIPC and GAIP form a complex with TrkA: a putative link between G protein and receptor tyrosine kinase pathways. Mol Biol Cell 12: 615-627.
6. Cai H, Reed RR (1999) Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 19: 6519-6527.
7. Gao Y, Li M, Chen W, Simons M (2000) Synectin, syndecan-4 cytoplasmic domain binding PDZ protein, inhibits cell migration. J Cell Physiol 184: 373-379.
8. Tkachenko E, Rhodes JM, Simons M (2005) Syndecans: new kids on the signaling block. Circ Res 96: 488-500.
9. Tan C, Deardorff MA, Saint-Jeannet JP, Yang J, Arzoumanian A, et al. (2001) Kermit, a frizzled interacting protein, regulates frizzled 3 signaling in neural crest development. Development 128: 3665-3674.
10. Ligensa T, Krauss S, Demuth D, Schumacher R, Camonis J, et al. (2001) A PDZ domain protein interacts with the C-terminal tail of the insulin-like growth factor-1 receptor but not with the insulin receptor. J Biol Chem 276: 33419-33427.
11. Blobe GC, Liu X, Fang SJ, How T, Lodish HF (2001) A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 276: 39608-39617.
12. Finger EC, Lee NY, You HJ, Blobe GC (2008) Endocytosis of the type III transforming growth factor-beta (TGF-beta) receptor through the clathrinindependent/ lipid raft pathway regulates TGF-beta signaling and receptor down-regulation. J Biol Chem 283: 34808-34818.
13. Rudchenko S, Scanlan M, Kalantarov G, Yavelsky V, Levy C, et al. (2008) A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen. BMC Cancer 8: 248.
14. Yavelsky V, Rohkin S, Shaco-Levy R, Tzikinovsky A, Amir T, et al. (2008) Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary. BMC Cancer 8: 247.
15. Kirikoshi H, Katoh M (2002) Up-regulation of GIPC2 in human gastric cancer. Int J Oncol 20: 1183-1187.
16. Kirikoshi H, Katoh M (2002) Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int J Mol Med 9: 509-513.
17. Muders MH, Baretton GB, Aust DE, Dutta SK, Wang E, et al. (2007) [GIPC: a new target for therapy in pancreatic adenocarcinoma?]. Verh Dtsch Ges Pathol 91: 286-293.
18. Muders MH, Dutta SK, Wang L, Lau JS, Bhattacharya R, et al. (2006) Expression and regulatory role of GAIP-interacting protein GIPC in pancreatic adenocarcinoma. Cancer Res 66: 10264-10268.
19. Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, et al. (2009) Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res 15: 4095-4103.
20. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
21. Culhane AC, Thioulouse J, Perriere G, Higgins DG (2005) MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics 21: 2789-2790.
22. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
23. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
24. Lottaz C, Yang X, Scheid S, Spang R (2006) OrderedList-a bioconductor package for detecting similarity in ordered gene lists. Bioinformatics 22: 2315-2316.
25. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA (2003) Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70.
26. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, et al. (2003) Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3: 483-495.
27. Goeman JJ, Oosting J, Cleton-Jansen AM, Anninga JK, van Houwelingen HC (2005) Testing association of a pathway with survival using gene expression data. Bioinformatics 21: 1950-1957.
28. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
29. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301.
30. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25: 1239-1246.
31. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
32. Keller-Pinter A, Bottka S, Timar J, Kulka J, Katona R, et al. (2010) Syndecan-4 promotes cytokinesis in a phosphorylation-dependent manner. Cell Mol Life Sci.
33. Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
34. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, et al. (2006) TM4 microarray software suite. Methods Enzymol 411: 134-193.
35. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
36. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.